Empirical Wealth Management’s Cognition Therapeutics CGTX Stock Holding History

Empirical Wealth Management’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$55.2K	Hold	48,000	–	–	﹤0.01%	1053
2026 Q1	$36.5K	Hold	48,000	–	–	﹤0.01%	985
2025 Q4	$64.8K	Hold	48,000	–	–	﹤0.01%	890
2025 Q3	$64.8K	Hold	48,000	–	–	﹤0.01%	787
2025 Q2	$14.9K	Buy	+48,000	New	+$16.2K	﹤0.01%	686

Other funds holding CGTX

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BSB

Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

BIA

Barry Investment Advisors New Bedford, Massachusetts $478M AUM 23.65% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

Empirical Wealth Management's CGTX Position: Q2 2026 in Review

Empirical Wealth Management held its Cognition Therapeutics (CGTX) position steady in Q2 2026 at 48,000 shares worth $55.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1053.

Empirical Wealth Management first reported a position in CGTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $64.8K in Q4 2025. 6 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

Empirical Wealth Management held 48,000 shares of Cognition Therapeutics worth $55.2K as of Q2 2026.
Empirical Wealth Management left its Cognition Therapeutics share count unchanged in Q2 2026.
Cognition Therapeutics made up ﹤0.01% of Empirical Wealth Management's portfolio in Q2 2026, its #1053 holding.
Empirical Wealth Management first reported a position in Cognition Therapeutics in Q2 2025 and has held it in 5 quarters since.
Empirical Wealth Management's Cognition Therapeutics position peaked at $64.8K in Q4 2025.
6 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Empirical Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.